PPI and Immune Agent Combination for Beta Cell Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diabetes treatments fail to reverse the underlying mechanism of the disease by not regenerating beta cells, leading to ongoing insulin dependence in type 1 and 2 diabetes patients, as they only focus on immune tolerance without addressing the need for beta cell regeneration.
Innovation Solution
The use of a proton pump inhibitor (PPI) in combination with an immune tolerance agent, such as cyclosporine, to increase gastrin levels and transform extra-islet pancreatic ductal tissue into new beta cells, providing both regeneration and protection from autoimmune destruction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune tolerance agents are used alone to treat diabetes, then autoimmune destruction of beta cells is blocked, but beta cell mass does not regenerate and patients remain insulin dependent
Solution Approach 1:
The patent combines two previously separate therapeutic approaches: immune tolerance agents (to protect existing beta cells from autoimmune destruction) and beta cell regeneration agents (to generate new beta cells). This merging of functions addresses both the protection and regeneration needs simultaneously, resolving the contradiction between blocking autoimmune destruction and regenerating beta cell mass.
Solution Approach 2:
The patent changes the therapeutic parameter from solely immunosuppression to a dual mechanism involving both immunosuppression and beta cell proliferation stimulation. By introducing agents that specifically target beta cell regeneration (such as gastrin, GLP-1 analogs, or other growth factors) alongside immune tolerance agents, the system transforms the treatment approach to simultaneously increase beta cell mass while protecting existing cells.
2Reliability
If current diabetes therapies are used, then blood glucose control is maintained, but the underlying mechanism of disease (lack of beta cells) is not reversed
Solution Approach 1:
The patent applies preliminary action by stimulating beta cell regeneration early in the disease process, before complete beta cell loss occurs. By initiating beta cell mass increase through regeneration agents while simultaneously providing immune protection, the treatment prevents further beta cell decline and establishes a foundation for long-term endogenous insulin production, rather than merely managing symptoms.
Solution Approach 2:
The patent enables the pancreas to serve itself by stimulating endogenous beta cell regeneration. Rather than relying entirely on exogenous insulin replacement, the treatment activates the body's own capacity to generate new beta cells through growth factors and regeneration agents, allowing the pancreatic tissue to repair and regenerate its insulin-producing capacity.
3Reliability
If immune tolerance therapy is implemented, then autoimmune attack is reduced, but sustained insulin independence is not achieved due to lack of beta cell regeneration
Solution Approach 1:
The patent merges immune tolerance therapy with beta cell regeneration therapy into a single integrated treatment regimen. This combination ensures that while existing beta cells are protected from autoimmune destruction, new beta cells are continuously generated to replace any that are lost and to increase overall beta cell mass, thereby sustaining insulin independence over the long term.
Solution Approach 2:
The patent establishes continuity of useful action by maintaining both immune protection and beta cell regeneration simultaneously over time. Rather than providing temporary relief followed by disease progression, the dual therapy continuously protects beta cells from immune attack while simultaneously generating new beta cells, creating a sustained therapeutic effect that maintains insulin independence.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy achieves insulin independence in type 1 and 2 diabetes patients by generating new beta cells and sustaining their function, addressing the limitations of previous treatments that relied solely on immune tolerance.
Implementation Method 1
PPIs may increase beta cell generation by their properties of increasing plasma gastrin levels as much as 9-fold, which in turn, transforms extra-islet pancreatic ductal tissue into new beta cells
Implementation Method 2
the immune tolerance agent protects the new beta cells generated by the PPI from autoimmune destruction
Data Source
AI summary
To date, no immune tolerance agent or combination of immune tolerance agents has been able to sustain insulin-independence among type 1 diabetes patients. This patent provides methods and pharmaceutical compositions for providing insulin independence among newly diagnosed and existing type 1 diabetes. Methods include utilization of PPIs, which increase gastrin resulting in the transformation of human ductal tissue into insulin-secreting new beta cells, used in combination with an immune tolerance agent to protect the new insulin-producing beta cells generated by the PPI from immune destruction. Compositions and methods are provided for beta cell generation therapy comprising at least one member from a group of PPIs with formulations selected from immune tolerance agents, when used in combination result in insulin-independence among new and existing type 1 patients whom currently require insulin to sustain life. Compositions and methods are provided for insulin-independence among type 2 patients using PPIs when combined with therapeutic agents utilized for the treatment of type 2 diabetes.